First-Line Treatment for Metastatic Clear-Cell Renal Cell Carcinoma with IMDC Favourable Risk

Clinical Scenario

This protocol addresses patients with metastatic clear-cell renal cell carcinoma who are stratified as IMDC favourable risk. The IMDC (International Metastatic RCC Database Consortium) risk classification is a central factor in selecting among the first-line treatment options available for this population.

Treatment Approach

First-line management in IMDC favourable risk disease encompasses several evidence-based systemic options — including both dual-agent combination regimens and established monotherapy alternatives. The complete set of recommended choices and the criteria for selecting among them are detailed in the full protocol.

Full regimen details, sequencing guidance, and supporting evidence are available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Offer pembrolizumab plus axitinib, lenvatinib plus pembrolizumab or nivolumab and cabozantinib or nivolumab plus ipilimumab or sunitinib or pazopanib for IMDC favourable risk disease.

View source ↗